Assuntos
Germinoma/fisiopatologia , Neoplasias Testiculares/fisiopatologia , Testículo/fisiologia , Adulto , Gonadotropina Coriônica/metabolismo , Fertilidade , Hormônio Foliculoestimulante/metabolismo , Seguimentos , Germinoma/metabolismo , Germinoma/terapia , Humanos , Hormônio Luteinizante/metabolismo , Masculino , Estudos Retrospectivos , Neoplasias Testiculares/metabolismo , Neoplasias Testiculares/terapiaRESUMO
Results in 503 patients with germ cell testicular tumors treated between 1982 and 1992 were analyzed. A follow-up program for germ cell tumors is presented which is related to the individual risk of tumor relapse. The overall relapse rate was 7%, of which 82% had recurrent tumor within 1 year after treatment. A low risk of relapse (3-5%) is seen in patients with seminoma stage I and radiation and, usually, in early-stage patients treated with polychemotherapy. A moderate risk of relapse (6-11%) is observed in patients with non-seminoma stage I and lymphadenectomy without chemotherapy. Seminoma without radiation and non-seminoma without lymphadenectomy in clinical stage I, non-seminoma stage IIa and IIb without adjuvant chemotherapy after lymphadenectomy, and primary high tumor mass present a high risk of relapse (> 11%). Tumor recurrence is localized mainly in lung and retroperitoneum. Most important in the follow-up are tumor marker and chest X-ray. During the first year examinations should take place every 3 months in the low-risk group and every 2 months in the moderate and high risk group. Computer tomography is only required in high-risk patients. Usually a 3-year follow-up is sufficient.
Assuntos
Assistência ao Convalescente/métodos , Neoplasias Embrionárias de Células Germinativas/terapia , Neoplasias Testiculares/terapia , Biomarcadores Tumorais/sangue , Quimioterapia Adjuvante , Terapia Combinada , Seguimentos , Humanos , Excisão de Linfonodo , Masculino , Recidiva Local de Neoplasia/mortalidade , Recidiva Local de Neoplasia/patologia , Recidiva Local de Neoplasia/terapia , Neoplasias Embrionárias de Células Germinativas/mortalidade , Neoplasias Embrionárias de Células Germinativas/patologia , Radioterapia Adjuvante , Fatores de Risco , Taxa de Sobrevida , Neoplasias Testiculares/mortalidade , Neoplasias Testiculares/patologiaRESUMO
The article describes analytical data for the screening and detection of nimetazepam and its major metabolites. The methods comprise thin-layer chromatography, gas chromatography, UV-spectrophotometry, infrared- and mass spectrometry.
Assuntos
Cromatografia em Camada Fina , Hipnóticos e Sedativos , Nitrazepam/análogos & derivados , Detecção do Abuso de Substâncias/métodos , Humanos , Nitrazepam/química , Nitrazepam/farmacocinéticaRESUMO
The paper describes a sensitive screening procedure for 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4- benzodiazepine-2-thione (quazepam, Oniria, Quazium) and its major metabolites.
Assuntos
Ansiolíticos/sangue , Benzodiazepinas/sangue , Ansiolíticos/metabolismo , Benzodiazepinas/metabolismo , Biotransformação , Cromatografia Gasosa , Humanos , Espectrometria de Massas , Espectrofotometria Infravermelho , Espectrofotometria UltravioletaRESUMO
The paper describes a sensitive method for the detection of 7-chloro-2,3-dihydro-5-phenyl-1-(2-propinyl)-1H-1,4-benzodiazepine -2-one (pinazepam, Domar) and its major metabolites.